Adaptive Stereotactic Radiotherapy Using Low-Dose CT Scans for Men 60 and Older with Localized Prostate Cancer

What this Trial Is About

Researchers are evaluating whether adaptive stereotactic body radiotherapy SBRT offers advantages over non-adaptive SBRT for treating localized prostate cancer in men aged 60 years and older. The study focuses on how anatomical changes, such as bladder filling and rectal volume, might affect radiation dosing. It also examines the overall dose delivered to nearby organs, patient quality of life over two years, and survival without cancer recurrence. Participants receive five low-dose, non-contrast CT scans taken immediately before each SBRT session to check for anatomical changes that could impact treatment. These scans help determine if recalculating the radiation dose is necessary to better target the prostate and protect surrounding organs. The study tracks these measurements across all five treatment sessions within approximately ten days. Throughout the study, patients report on their quality of life and urinary symptoms before treatment and at several points up to 24 months after radiotherapy. Researchers monitor survival and cancer recurrence at multiple intervals within the two-year follow-up. Participants are carefully informed and provide consent, with ongoing evaluations to assess treatment impact and safety over time.

Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer